Genetic variants in the ADAMTS13 and SUPT3H genes are associated with ADAMTS13 activity

Blood

Volumn 125, Issue 25, 2015, Pages 3949-3955

  De Vries, Paul S ^a   Boender, Johan ^a   Sonneveld, Michelle A H ^a   Rivadeneira, Fernando ^a   Ikram, M Arfan ^a   Rottensteiner, Hanspeter ^b   Hofman, Albert ^a   Uitterlinden, André G ^a   Leebeek, Frank W G ^a   Franco, Oscar H ^a   Dehghan, Abbas ^a   De Maat, Moniek P M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b BAXTER INNOVATIONS GMBH   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEINS; ADAMTS13 PROTEIN, HUMAN; SUPT3H PROTEIN, HUMAN; TRANSCRIPTION FACTORS;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; EXOME; EXON; FEMALE; GENE; GENE ACTIVITY; GENE REPLICATION; GENETIC ASSOCIATION; GENETIC CODE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; PRIORITY JOURNAL; SUPT3H GENE; COHORT STUDIES; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENETIC VARIATION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE;

ADAM PROTEINS; AGED; COHORT STUDIES; EXOME; FEMALE; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANSCRIPTION FACTORS;

EID: 84934949422     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-02-629865     Document Type: Article

References (46)

1. Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood. 2001;98(6):1662-1666.
2. Gerritsen HE, Robles R, Lämmle B, Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood. 2001;98(6):1654-1661.
3. Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 2001;276(44):41059-41063.
4. Tsai HM. Thrombotic thrombocytopenic purpura: a thrombotic disorder caused by ADAMTS13 deficiency. Hematol Oncol Clin North Am. 2007;21(4):609-632, v. [v.].
5. Bongers TN, de Bruijne EL, Dippel DW, et al. Lower levels of ADAMTS13 are associated with cardiovascular disease in young patients. Atherosclerosis. 2009;207(1):250-254.
6. Sonneveld MA, de Maat MP, Leebeek FW. Von Willebrand factor and ADAMTS13 in arterial thrombosis: a systematic review and meta-analysis. Blood Rev. 2014;28(4):167-178.
7. Andersson HM, Siegerink B, Luken BM, et al. High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women. Blood. 2012;119(6):1555-1560.
8. Chion CK, Doggen CJ, Crawley JT, Lane DA, Rosendaal FR. ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men. Blood. 2007;109(5):1998-2000.
9. Crawley JT, Lane DA, Woodward M, Rumley A, Lowe GD. Evidence that high von Willebrand factor and low ADAMTS-13 levels independently increase the risk of a non-fatal heart attack. J Thromb Haemost. 2008;6(4):583-588.
10. Tseng SC, Kimchi-Sarfaty C. SNPs in ADAMTS13. Pharmacogenomics. 2011;12(8):1147-1160.
11. Lotta LA, Garagiola I, Palla R, Cairo A, Peyvandi F. ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. Hum Mutat. 2010;31(1):11-19.
12. Hofman A, Darwish Murad S, van Duijn CM, et al. The Rotterdam Study: 2014 objectives and design update. Eur J Epidemiol. 2013;28(11):889-926.
13. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol. 1991;7(4):403-422.
14. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol. 2005;129(1):93-100.
15. Boomsma DI, Wijmenga C, Slagboom EP, et al. The Genome of the Netherlands: design, and project goals. Eur J Hum Genet. 2014;22(2):221-227.
16. Deelen P, Menelaou A, van Leeuwen EM, et al Genome of Netherlands Consortium. Improved imputation quality of low-frequency and rare variants in European samples using the 'Genome of The Netherlands'. Eur J Hum Genet. 2014;22(11):1321-1326.
17. Genome of the Netherlands Consortium. Whole-genome sequence variation, population structure and demographic history of the Dutch population. Nat Genet. 2014;46(8):818-825.
18. Grove ML, Yu B, Cochran BJ, et al. Best practices and joint calling of the HumanExome BeadChip: the CHARGE Consortium. PLoS ONE. 2013;8(7):e68095.
19. Aulchenko YS, Struchalin MV, van Duijn CM. ProbABEL package for genome-wide association analysis of imputed data. BMC Bioinformatics. 2010;11:134.
20. Pruim RJ, Welch RP, Sanna S, et al. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics. 2010;26(18):2336-2337.
21. Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res. 2012;40(Database issue):D930-D934.
22. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489(7414):57-74.
23. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics. 2010;26(17):2190-2191.
24. Liu X, Jian X, Boerwinkle E. dbNSFP: a lightweight database of human nonsynonymous SNPs and their functional predictions. Hum Mutat. 2011;32(8):894-899.
25. Peloso GM, Auer PL, Bis JC, et al; NHLBI GO Exome Sequencing Project. Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 whites and blacks. Am J Hum Genet. 2014;94(2):223-232.
26. Wu MC, Lee S, Cai T, Li Y, Boehnke M, Lin X. Rare-variant association testing for sequencing data with the sequence kernel association test. Am J Hum Genet. 2011;89(1):82-93.
27. Mathieson I, McVean G. Differential confounding of rare and common variants in spatially structured populations. Nat Genet. 2012;44(3):243-246.
28. Yang J, Benyamin B, McEvoy BP, et al. Common SNPs explain a large proportion of the heritability for human height. Nat Genet. 2010;42(7):565-569.
29. Plaimauer B, Fuhrmann J, Mohr G, et al. Modulation of ADAMTS13 secretion and specific activity by a combination of common amino acid polymorphisms and a missense mutation. Blood. 2006;107(1):118-125.
30. Jenkins PV, O'Donnell JS. ABO blood group determines plasma von Willebrand factor levels: a biologic function after all? Transfusion. 2006;46(10):1836-1844.
31. Bowen DJ. An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13. J Thromb Haemost. 2003;1(1):33-40.
32. Yu J, Madison JM, Mundlos S, Winston F, Olsen BR. Characterization of a human homologue of the Saccharomyces cerevisiae transcription factor spt3 (SUPT3H). Genomics. 1998;53(1):90-96.
33. Martinez E, Kundu TK, Fu J, Roeder RG. A human SPT3-TAFII31-GCN5-L acetylase complex distinct from transcription factor IID. J Biol Chem. 1998;273(37):23781-23785.
34. Verdone L, Caserta M, Di Mauro E. Role of histone acetylation in the control of gene expression. Biochem Cell Biol. 2005;83(3):344-353.
35. Lee TI, Causton HC, Holstege FC, et al. Redundant roles for the TFIID and SAGA complexes in global transcription. Nature. 2000;405(6787):701-704.
36. Eisenmann DM, Arndt KM, Ricupero SL, Rooney JW, Winston F. SPT3 interacts with TFIID to allow normal transcription in Saccharomyces cerevisiae. Genes Dev. 1992;6(7):1319-1331.
37. Claus RA, Bockmeyer CL, Kentouche K, et al. Transcriptional regulation of ADAMTS13. Thromb Haemost. 2005;94(1):41-45.
38. Gill G, Pascal E, Tseng ZH, Tjian R. A glutaminerich hydrophobic patch in transcription factor Sp1 contacts the dTAFII110 component of the Drosophila TFIID complex and mediates transcriptional activation. Proc Natl Acad Sci USA. 1994;91(1):192-196.
39. De Cock E, Hermans C, De Raeymaecker J, et al. The novel ADAMTS13-p.D187H mutation impairs ADAMTS13 activity and secretion and contributes to thrombotic thrombocytopenic purpura in mice. J Thromb Haemost. 2015;13(2):283-292.
40. de Groot R, Lane DA, Crawley JT. The ADAMTS13 metalloprotease domain: roles of subsites in enzyme activity and specificity. Blood. 2010;116(16):3064-3072.
41. Camilleri RS, Cohen H, Mackie IJ, et al. Prevalence of the ADAMTS-13 missense mutation R1060W in late onset adult thrombotic thrombocytopenic purpura. J Thromb Haemost. 2008;6(2):331-338.
42. Rurali E, Noris M, Chianca A, et al BENEDICT Study Group. ADAMTS13 predicts renal and cardiovascular events in type 2 diabetic patients and response to therapy. Diabetes. 2013;62(10):3599-3609.
43. Miyata T, Kokame K, Matsumoto M, Fujimura Y. ADAMTS13 activity and genetic mutations in Japan. Hamostaseologie. 2013;33(2):131-137.
44. Kokame K, Kokubo Y, Miyata T. Polymorphisms and mutations of ADAMTS13 in the Japanese population and estimation of the number of patients with Upshaw-Schulman syndrome. J Thromb Haemost. 2011;9(8):1654-1656.
45. Tsai HM, Sussman II, Ginsburg D, Lankhof H, Sixma JJ, Nagel RL. Proteolytic cleavage of recombinant type 2A von Willebrand factor mutants R834W and R834Q: inhibition by doxycycline and by monoclonal antibody VP-1. Blood. 1997;89(6):1954-1962.
46. Crawley JT, Lam JK, Rance JB, Mollica LR, O'Donnell JS, Lane DA. Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood. 2005;105(3):1085-1093.